Zhihao Wei, Jiankun Jia, Gang Heng, Huailong Xu, Juanjuan Shan, Guiqin Wang, Chungang Liu, Jianyu Xia, Haijun Zhou, Min Wu, Zhi Yang, Meiling Wang, Zhouxing Xiong, Hong Huang, Limei Liu, Cheng Qian – 22 March 2019 – Metabolic reprogramming endows cancer cells with the ability to adjust metabolic pathways to support heterogeneously biological processes. However, it is not known how the reprogrammed activities are implemented during differentiation of cancer stem cells (CSCs).

Daniel Azoulay, Chady Salloum, Rony Eshkenazi, Chaya Shwaartz, Eylon Lahat, Chetana Lim – 22 March 2019

Keiichi Fujiwara, Masayuki Nakano, Shin Yasui, Osamu Yokosuka, Naoya Kato – 22 March 2019

Scott McHenry, Nicholas O. Davidson – 22 March 2019

Mussarat N. Rahim, Rodrigo Liberal, Rosa Miquel, Nigel D. Heaton, Michael A. Heneghan – 22 March 2019 – Acute severe presentations of autoimmune hepatitis (AIH) represent a challenge for the transplant community. As a disease, it is poorly characterized, and there is a weak evidence base to guide diagnosis and treatment. Early identification of acute severe AIH is key because it determines the initiation of corticosteroids, which can be lifesaving. However, their use in this setting remains controversial.

Banishree Saha, David Tornai, Karen Kodys, Adeyinka Adejumo, Patrick Lowe, Craig McClain, Mack Mitchell, Arthur McCullough, Srinivasan Dasarathy, Aimee Kroll‐Desrosiers, Bruce Barton, Svetlana Radaeva, Gyongyi Szabo – 19 March 2019 – Although mortality due to acute alcoholic hepatitis (AH) correlates with Model for End‐Stage Liver Disease (MELD) scores, biomarkers are critically needed to manage this disease. Increases in inflammatory markers and macrophage activation are associated with acute AH and could be potential biomarkers of clinical events and/or mortality.

Narendra S. Choudhary, Sanjiv Saigal, Neeraj Saraf, Arvinder S. Soin – 18 March 2019

Felix Piecha, Jan‐Michael Gänßler, Sabine Jordan, Can Ergen, Harald Ittrich, Johannes Kluwe, Sven Pischke, Ansgar W. Lohse, Julian Schulze zur Wiesch – 18 March 2019 – Direct‐acting antiviral (DAA) therapies have revolutionized the treatment of chronic hepatitis C virus infection, achieving sustained virological response (SVR) rates of >90% even in patients with advanced liver cirrhosis.

Jian He, Ai‐Min Leng – 18 March 2019

Connie W. Wang, Adrienne Lebsack, Stephanie Chau, Jennifer C. Lai – 18 March 2019 – The Liver Frailty Index (LFI), composed of 3 performance‐based tests (grip strength, chair stands, and balance), is a tool specifically developed in patients with cirrhosis to objectively measure physical function, a critical determinant of health outcomes.